Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jodie Pope Morrison
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 22
- Beta
- -0.33
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 14.63
Financials
Revenue
$0.00-100.0%Net Income
$-8.95MEBITDA
$-8.77MFree Cash Flow
$-3.08M-114.2%EPS (diluted)
$-0.44Shares Outstanding (diluted)
14.10M+577.8%Operating Expenses
$9.12MCash & Debt
$106.27MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $53.74M | $29.82M | $2.42 |
| 2024 | $0.00 | $-47.73M | $-5.12 |
| 2023 | $-6.65M | $-53.74M | $-4.51 |
| 2022 | $6.65M | $-42.81M | $-3.59 |
| 2021 | $0.00 | $-37.56M | $-3.15 |
| 2020 | $2.70M | $-128.69M | $-50.46 |
| 2019 | $1.67M | $-103.92M | $-44.41 |
| 2018 | $5.32M | $-55.58M | $-35.04 |
| 2017 | $0.00 | $-29.99M | $-14.42 |
| 2016 | $0.00 | $-8.05M | $-3.87 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $3.56
- Implied price
- $64.12
- Return from $8.23
- 50.8% a year
To earn 15.0% a year on these assumptions you'd need to buy at $31.88 — today's price is already 74.2% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -2.0% | 26.2% | 31.9% | 36.8% | 41.1% | 44.9% |
| 3.0% | 32.6% | 38.6% | 43.8% | 48.3% | 52.3% |
| 8.0% | 39.0% | 45.4% | 50.8% | 55.5% | 59.7% |
| 13.0% | 45.5% | 52.1% | 57.8% | 62.7% | 67.1% |
| 18.0% | 51.9% | 58.8% | 64.7% | 69.9% | 74.5% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
95-5.00%Social Signal Score
Mentions (6)
- Newsprnewswire.com·6d ago·Neutral
… areata; Q32 Bio intends to advance a registration-directed program in the first half of 2027 -- WALTHAM, Mass., Sept. 30, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical-stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced additional 36-week results and initial findings from the 16-week off-drug period from Part B of the SIGNAL-AA Phase 2a clinical trial evaluati…
View source ↗ - Newsseekingalpha.com·9d ago·Neutral
Q32 Bio: Durable Hair Regrowth Remains The Goal Q32 Bio'S bempikibart could offer lasting hair regrowth in alopecia areata, but its potential advantage still depends on broader clinical validation. For now, QTTB's improved financing gives them room to maneuver in the short term, which helps de-risk the stock as well. That means QTTB's subsequent updates by 2H2026, 1H2027, and 2H2027 are what will ultimately make or break my bull case on the stock.
View source ↗ - Newsprnewswire.com·15d ago·Negative
…off-drug period from Part B of the SIGNAL-AA clinical trial of bempikibart in alopecia areata -- WALTHAM, Mass., Sept. 21, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical-stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced that additional 36-week results and initial findings from the 16-week off-drug period from Part B of the SIGNAL-AA Phase 2a clinical trial eva…
View source ↗ - Newsseekingalpha.com·20d ago·Positive
Q32 Bio Inc. (QTTB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Q32 Bio Inc. (QTTB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newszacks.com·28d ago·Neutral
Down 23.1% in 4 Weeks, Here's Why Q32 Bio (QTTB) Looks Ripe for a Turnaround The heavy selling pressure might have exhausted for Q32 Bio (QTTB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
View source ↗ - Newszacks.com·49d ago·Neutral
Wall Street Analysts See an 182.18% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High? The average of price targets set by Wall Street analysts indicates a potential upside of 182.2% in Q32 Bio (QTTB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.36 per share
Typical surprise +26.8% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-0.44 vs $-0.53beat
- Tue, May 5$-0.54 vs $-0.68beat
- Tue, Mar 10$3.65 vs $-0.85beat
- Thu, Nov 13$-0.60 vs $-1.39beat
- Wed, Aug 6$-0.78 vs $-1.14beat
- Thu, May 8$-0.90 vs $-1.23beat
Estimates and results for QTTB via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by QTTB officers and directors.
- Bought
- $30.0m
- Sold
- $492k
4 trades
11 trades
- Morrison Jodie Popesold
- Kalowski Leesold
- Violette Shelia M.sold
- Xu Diyongbought
- Xu Diyongbought
- Orbimed Advisors Llcbought
- Orbimed Advisors Llcbought
- Kalowski Leesold
85 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in QTTB.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.